Crossing the Blood–Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies
Pharmaceutics · 28.05.2025 · 17 (6) · 706
DOI: 10.3390/pharmaceutics17060706 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 28.05.2025. Verfasst von Ling Ding und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, NE 68198, USA. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The blood–brain barrier (BBB) is a highly selective and natural protective membrane that restricts the entry of therapeutic agents into the central nervous system (CNS). This restrictive nature poses a major challenge for pharmacological treatment of a wide range of CNS disorders, including neurodegenerative disorders, brain tumors, and psychiatric conditions. Many chemical drugs and biopharmaceuticals are unable to cross the BBB, and conventional drug delivery methods often fail to achieve sufficient brain concentrations, leading to reduced therapeutic efficacy and increased risk of systemic toxicity. In recent years, targeted drug delivery strategies have emerged as promising approaches to overcome the BBB and enhance the delivery of therapeutic agents to the brain. Among these, receptor-mediated transcytosis (RMT) and transporter-mediated transcytosis (TMT) are two of the most extensively studied mechanisms for transporting drugs across brain endothelial cells into the brain parenchyma. Advances in materials science and nanotechnology have facilitated the development of multifunctional carriers with optimized properties, improving drug targeting, stability, and release profiles within the brain. This review summarizes the physiological structure of the BBB and highlights recent innovations in RMT- and TMT-mediated brain drug delivery systems, emphasizing their potential not only to overcome current challenges in CNS drug development, but also to pave the way for next-generation therapies that enable more precise, effective, and personalized treatment of brain-related diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
ORCID-Profile: Ling Ding, Pratiksha Kshirsagar, Prachi Agrawal, Daryl J Murry
Zitieren
APA
Ding, L., Kshirsagar, P., Agrawal, P., & Murry, D. J. (2025). Crossing the Blood–Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies. Pharmaceutics, 17(6), 706. https://doi.org/10.3390/pharmaceutics17060706
Vancouver
Ding L, Kshirsagar P, Agrawal P, Murry DJ. Crossing the Blood–Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies. Pharmaceutics. 2025;17(6):706. doi:10.3390/pharmaceutics17060706
BibTeX
@article{Ding2025,
author = {Ding, Ling and Kshirsagar, Pratiksha and Agrawal, Prachi and Murry, Daryl J},
title = {Crossing the Blood–Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {6},
pages = {706},
doi = {10.3390/pharmaceutics17060706}
}
EUVIMED